Evidence map›Paper›PMID 30622555›Full record

ArticleFrontiers in genetics2018

Introducing WikiPathways as a Data-Source to Support Adverse Outcome Pathways for Regulatory Risk Assessment of Chemicals and Nanomaterials.

Marvin Martens, Tim Verbruggen, Penny Nymark, Roland Grafström, Lyle D Burgoon, Hristo Aladjov, Fernando Torres Andón, Chris T Evelo, Egon L Willighagen

Abstract read
In one paragraph

Article in Frontiers in genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Unveiling toxicological adverse outcomes: toward construction and simulation of large-scale networks.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Towards a qAOP framework for predictive toxicology - Linking data to decisions.Computational toxicology (Amsterdam, Netherlands) · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. WikiPathways: connecting communities.Nucleic acids research · 2021
    Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marvin MartensDepartment of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, Netherlands.
Tim VerbruggenDepartment of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, Netherlands.
Penny NymarkInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Roland GrafströmInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Lyle D BurgoonU.S. Army Engineer Research and Development Center, Vicksburg, MS, United States.
Hristo AladjovOrganisation for Economic Co-operation and Development Environment Directorate, Paris, France.
Fernando Torres AndónLaboratory of Cellular Immunology, Humanitas Clinical and Research Institute, Rozzano, Italy.
Chris T EveloDepartment of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, Netherlands.
Egon L WillighagenDepartment of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A paradigm shift is taking place in risk assessment to replace animal models, reduce the number of economic resources, and refine the methodologies to test the growing number of chemicals and nanomaterials. Therefore, approaches such as transcriptomics, proteomics, and metabolomics have become valuable tools in toxicological research, and are finding their way into regulatory toxicity. One promising framework to bridge the gap between the molecular-level measurements and risk assessment is the concept of adverse outcome pathways (AOPs). These pathways comprise mechanistic knowledge and connect biological events from a molecular level toward an adverse effect outcome after exposure to a chemical. However, the implementation of omics-based approaches in the AOPs and their acceptance by the risk assessment community is still a challenge. Because the existing modules in the main repository for AOPs, the AOP Knowledge Base (AOP-KB), do not currently allow the integration of omics technologies, additional tools are required for omics-based data analysis and visualization. Here we show how WikiPathways can serve as a supportive tool to make omics data interoperable with the AOP-Wiki, part of the AOP-KB. Manual matching of key events (KEs) indicated that 67% could be linked with molecular pathways. Automatic connection through linkage of identifiers between the databases showed that only 30% of AOP-Wiki chemicals were found on WikiPathways. More loose linkage through gene names in KE and Key Event Relationships descriptions gave an overlap of 70 and 71%, respectively. This shows many opportunities to create more direct connections, for example with extended ontology annotations, improving its interoperability. This interoperability allows the needed integration of omics data linked to the molecular pathways with AOPs. A new AOP Portal on WikiPathways is presented to allow the community of AOP developers to collaborate and populate the molecular pathways that underlie the KEs of AOP-Wiki. We conclude that the integration of WikiPathways and AOP-Wiki will improve risk assessment because omics data will be linked directly to KEs and therefore allow the comprehensive understanding and description of AOPs. To make this assessment reproducible and valid, major changes are needed in both WikiPathways and AOP-Wiki.

Indexed as

adverse outcome pathwaysinteroperabilityomicsrisk assessmentWikiPathways

Identifiers

PMID30622555
PMCPMC6308971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.